Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose
Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of
a dose of COMIRNATY after a previous single dose of VAXZEVRIA. A stratification will be made
based on the following factors: study site, sex and age. This protocol allows to test the
immunogenicity and safety of a heterologous vaccination strategy after a previous single dose
of VAXZEVRIA.
Phase:
Phase 2
Details
Lead Sponsor:
Instituto de Investigación Hospital Universitario La Paz
Collaborators:
Instituto de Salud Carlos III Spanish Clinical Research Network - SCReN